Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Callan Family Office LLC

Key Points

• Callan Family Office LLC increased its stake in Zimmer Biomet Holdings by 66.5% in the first quarter, bringing its holdings to $2.06 million across 18,163 shares.
• Insider Sang Yi sold 1,000 shares of Zimmer Biomet at an average price of $95.00, resulting in a 4.67% decrease in their ownership.
• Zimmer Biomet reported a quarterly earnings per share of $2.07, exceeding expectations, alongside a 7.0% increase in revenue compared to the same quarter last year.

Callan Family Office LLC lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 66.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,163 shares of the medical equipment provider's stock after buying an additional 7,252 shares during the quarter. Callan Family Office LLC's holdings in Zimmer Biomet were worth $2,056,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Zimmer Biomet by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider's stock valued at $2,609,130,000 after purchasing an additional 166,763 shares during the period. Dodge & Cox raised its stake in Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock valued at $2,019,480,000 after purchasing an additional 2,044,645 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Zimmer Biomet by 1.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock valued at $1,559,147,000 after purchasing an additional 176,337 shares during the period. Northern Trust Corp raised its stake in Zimmer Biomet by 7.6% during the 4th quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider's stock valued at $250,367,000 after purchasing an additional 167,435 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Zimmer Biomet by 251.3% during the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock valued at $235,571,000 after purchasing an additional 1,488,918 shares during the period. Institutional investors own 88.89% of the company's stock.

Insider Transactions at Zimmer Biomet

In related news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the transaction, the insider directly owned 20,424 shares of the company's stock, valued at $1,940,280. This represents a 4.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 1.39% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Roth Capital restated a "buy" rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Truist Financial set a $101.00 price target on Zimmer Biomet in a report on Tuesday, May 6th. The Goldman Sachs Group cut their price target on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. Canaccord Genuity Group cut their price target on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a report on Monday, May 12th. Finally, Evercore ISI cut their price target on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $111.44.

Zimmer Biomet Stock Down 1.1%

Shares of ZBH stock traded down $1.10 during mid-day trading on Thursday, hitting $102.12. The stock had a trading volume of 1,525,117 shares, compared to its average volume of 1,854,930. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $116.71. The firm has a market capitalization of $20.23 billion, a P/E ratio of 24.85, a price-to-earnings-growth ratio of 2.35 and a beta of 0.68. The firm's 50-day moving average is $94.15 and its two-hundred day moving average is $99.54. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%. The business had revenue of $2.08 billion during the quarter, compared to analysts' expectations of $2.06 billion. During the same period in the prior year, the business earned $2.01 EPS. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, July 31st. Investors of record on Thursday, June 26th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, June 26th. Zimmer Biomet's dividend payout ratio is currently 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.